Both in Pharmaceuticals
PDS Biotechnology vs Perspective Therapeutics
Over the past year PDSB returned +50.9% and CATX returned −66.2%; their daily moves had a correlation of 0.02.
PDSB +50.9% CATX −66.2%Growth of $1, one year, split-adjusted
| Metric | PDSB | CATX |
|---|---|---|
| Price | $1.41 | $0.8800 |
| Market cap | $102.2M | $100.5M |
| Today | +2.92% | −15.38% |
| 1 month | +17.5% | −65.8% |
| 6 months | +33.0% | −75.9% |
| Year to date | +83.2% | −68.0% |
| 1 year | +50.8% | −67.8% |
| Revenue growth (YoY) | — | −72.1% |
| Gross margin | — | 100.0% |
| Net margin | — | −33069.1% |
| P/E (TTM) | — | — |
| Price / sales | — | 245.6× |
| Net cash | $1.2M | $235.3M |
| Dividend yield | — | — |
| Volatility (60d) | 315.6% | 118.2% |
| Short % of float | 8.6% | 17.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).